-Review-

Development of Biomarkers to Predict Recurrence by Determining the Metastatic Ability of Cancer Cells

Kazufumi Honda

Department of Bioregulation, Institution for Advanced Medical Science, Nippon Medical School, Tokyo, Japan

Adjuvant chemotherapy is administered to cancer patients after curative resection but is unnecessary when patients without micro-metastatic lesions undergo a perfectly curative surgical procedure. Patients who need adjuvant chemotherapy are those with micro-metastases outside the resection area that are not detectable by imaging, despite curative resection at primary sites. If biomarkers that reflect metastatic potential could be developed, personalized adjuvant chemotherapy could be provided in clinical settings. Actinin-4 (ACTN4, gene name ACTN4) is an actin-bundling protein identified in 1998 as a novel molecule involved in cancer invasion and metastasis. Overexpression of actinin-4 protein in cancer cells leads to an invasive phenotype, and patients with gene amplification of ACTN4 have a worse prognosis than patients with a normal copy number for cancers of the pancreas, lung, and salivary glands, among others. This review summarizes the biological roles of actinin-4 in cancer invasion and metastasis and examines the potential usefulness of actinin-4 as a biomarker for evaluation of metastatic ability.

J Nippon Med Sch 2022; 89: 24-32

Keywords
biomarker, metastatic ability, actin-bundling protein, ACTN4

Correspondence to
Kazufumi Honda, Department of Bioregulation, Institution for Advanced Medical Science, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan
k-honda@nms.ac.jp

Received, June 25, 2021
Accepted, August 4, 2021